3 ms·
FWIW, Novo Nordisk also tried to kill their GLP-1 effort several times according to the project lead, Lotte Bjerre Knudsen: https://archive.is/oLnBl https://arc
by nextos 10mo ago
FWIW, Novo Nordisk also tried to kill their GLP-1 effort several times according to the project lead, Lotte Bjerre Knudsen: https://archive.is/oLnBl https://archive.is/oLnBl
In large organizations, I guess a big chunk of success comes from being able to navigate all these political ups and downs.
- RobotToaster 10mo agoI wonder how many other great medical innovations have disappeared because of such bureaucracy.
- DANmode 10mo agoHow long do you have? https://www.sciencenews.org/article/vaccine-beer-polyomavirus-chris-buck https://www.sciencenews.org/article/vaccine-beer-polyomaviru...
- estearum 10mo agoBureaucracy? This is the same type of go/no-go decision that R&D orgs have to make with incomplete information and immense costs every day. But with less complete information (no in-human data → 70-90% failure rate) and more immense costs (a couple hundred million dollars to get it through trials). The problem is the cost and risk profile of drug development. With those parameters where they are, there will be countless "bureaucratic errors" of foregone opportunities, most of which we'll never even learn about.
- lotsofpulp 10mo agoTechnically, they disappeared because of limited resources. If every pharmaceutical organization had unlimited funding to run unlimited trials, then they would.